Syed et al. (2013) developed a keloid organ culture model for evaluating the antifibrotic bioactives in scarring and found that EGCG treatment decreased the size of the keloid, suppressed intrakeloid proliferation, reduced collagen production and downregulated the transcription of major fibrosis-related pathways, including VEGF, matrix metalloproteinases (MMP-2 and -9) and TGF-β2 [70]. The gene discussed is MMP2; the disease is keloid.